Renoprotective Effects of a New Free Radical Scavenger, XH-003, against Cisplatin-Induced Nephrotoxicity

Acute renal injury has an incidence of 25%–30% in patients with tumors who are treated with cisplatin and in patients for whom no specific drugs are available for treatment. Amifostine is the only FDA-approved chemoprotective drug; however, its clinical application is limited because of side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ya-Hong, Li, Kui, Tian, Hong-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189338/
https://www.ncbi.nlm.nih.gov/pubmed/32377314
http://dx.doi.org/10.1155/2020/9820168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189338/
https://www.ncbi.nlm.nih.gov/pubmed/32377314
http://dx.doi.org/10.1155/2020/9820168

Ejemplares similares